Recce Pharmaceuticals Ltd

OTCPK:RECE.F Stock Report

Market Cap: US$67.2m

Recce Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RECE.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies12,807,7895.78%
Institutions19,644,4668.86%
Individual Insiders64,774,14829.2%
General Public124,538,62956.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.4%.

Top Shareholders

Top 23 shareholders own 43.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.7%
Graham John Melrose
34,828,311US$10.6m-5.94%no data
6.83%
Fidelity International Ltd
15,144,466US$4.6m0%no data
4.44%
James Graham
9,844,487US$3.0m45.5%no data
2.14%
Mark Rogers
4,750,000US$1.4m35.7%no data
2.14%
A. Veliss
4,750,000US$1.4m35.7%no data
2.03%
Acuity Capital Investment Management Pty Ltd, Asset Management Arm
4,500,000US$1.4m0%2.96%
1.49%
Acewood Investments Pty Ltd
3,307,101US$1.0m3.85%no data
1.43%
Pejay Pty Limited
3,175,000US$962.7k27%no data
1.29%
John Liddelow
2,850,486US$864.3k-2.05%no data
1.28%
Michele Dilizia
2,828,485US$857.6k4.48%no data
1.06%
Ldu Pty Ltd
2,355,688US$714.3k9.88%no data
0.95%
Querion Pty Ltd.
2,100,000US$636.7k0%no data
0.84%
Haultrans Management Pty Limited
1,870,000US$567.0k3.89%no data
0.59%
Mark Swinn
1,314,720US$398.6k0%no data
0.32%
Michael Aarons
718,749US$217.9k0%no data
0.32%
Mami Aarons
718,749US$217.9k0%no data
0.3%
Nikolai Shirobokov
670,982US$203.4k13.5%no data
0.3%
Svetlana Shirobokov
670,981US$203.4k13.5%no data
0.14%
John K. Prendergast
306,819US$93.0k0%no data
0.14%
Justin Ward
301,444US$91.4k0%no data
0.057%
Alan Dunton
126,819US$38.5k0%no data
0.03%
Arthur Kollaras
67,155US$20.4k0%no data
0.012%
Alistair McKeough
25,961US$7.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 08:06
End of Day Share Price 2024/05/08 00:00
Earnings2023/12/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pooya HemamiEdison Investment Research
Chris KallosMST Financial Services Pty Limited